SynthesisBMC anesthesiology2026
Comparison of liposomal bupivacaine and regular bupivacaine in the transversus abdominis plane for postoperative analgesia: an updated systematic review and meta-analysis.
Synthesis in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLiposome bupivacaine is a long-acting anesthetic to prolong the duration of analgesia. However, the effectiveness of liposome bupivacaine for providing prolonged analgesia with transversus abdominis plane (TAP) blocks remains uncertain. Therefore, we performed a systematic review and meta-analysis to compare the analgesic efficacy of liposome bupivacaine to regular bupivacaine in TAP blocks.
methodsPubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to December 2024. Randomized controlled trials (RCTs) comparing liposome bupivacaine and regular bupivacaine in TAP blocks were included in this analysis. The primary outcomes were morphine milligram equivalents (MMEs) in the first 24 h and second 24 h after surgery. Secondary outcomes were pain scores at 24 h and 48 h postoperatively, length of hospital stay, and opioid-related side effects.
results13 RCTs including 1195 patients were eligible for meta-analysis. The use of liposome bupivacaine in TAP blocks significantly decreased opioid requirement (WMD, -2.40; 95% CI, -4.47 to -0.34; I2 = 78.2%; P = 0.023) in the first 24 h after surgery. No difference was found in the opioid consumption in the second 24 h between the liposome bupivacaine and regular bupivacaine groups. Moreover, no significant difference in pain scores up to 48 h, length of hospital stay, and incidence of opioid-related side effects was found between the two groups.
conclusionLiposomal bupivacaine for TAP blocks significantly reduced 24-hour opioid consumption (WMD = -2.40 MMEs) but provided no clinically meaningful benefits in pain control, prolonged analgesia, length of stay, or adverse events. Routine use cannot be justified given its higher cost.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.